Entries by Maren Kühr

New CEO appointed

Matt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.

Experienced CMO on board

The French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.

Aequorin: superior choice for GPCR calcium signalling

The study of G protein-coupled receptor (GPCR) signalling is crucial for ­understanding a wide range of physiological processes. Among the methods used to monitor ­calcium ­signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment ­targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.

CEO and Chairman of the Executive Board

French Innate Pharma SA announced the appointment of Jonathan Dickinson as the Company’s newChief Executive Officer (CEO) and Chairman of the Executive Board. He succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.

Sustainable, automated, ULT storage

The volume of samples and drug products requiring -80°C storage continues to increase, and shows no sign of slowing down. For many organisations, meeting these growing ULT ­storage ­requirements is challenging. The sheer volume of samples necessitates extensive storage capacity, which demands significant space, substantial energy use, and intensive management. Centralising and automating sample storage can provide a comprehensive solution.

Pichia protein production

Recombinant protein production in Pichia typically relies on AOX1 ­promoter-driven expression using methanol for induction. However, some companies avoid methanol due to safety concerns or operational demands. VALIDOGEN’s unique AOX1 promoter variants enable methanol-free protein production at high space-time yields, offering advantages beyond safety. Latest case studies underscore the strength of this technology.

Focus on long-term protection

Multiple sclerosis is currently an incurable, chronic autoimmune disease. While it is possible to effectively manage the feared relapses with existing therapies, novel approaches aim to provide important protection against long-term impairments.

Ensuring sustainability and continuity in biomanufacturing

Biomanufacturers must balance the development of new therapeutic modalities and reduce manufacturing costs while maintaining environmental responsibility. Efforts are centred on improving process robustness and efficiency and creating more flexible manufacturing facilities that can accommodate diverse biopharmaceutical products.